Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings
CEO & Managing Director, Kate Munnings
Source: Virtus Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Virtus Health (VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the State Governments cope with the current COVID-19 outbreak
  • In NSW, all non-urgent elective surgeries have been suspended from January 10 but this does not apply to procedures where patients are admitted and dischared on the same day
  • The Victorian State Government has suspended all non-urgent elective surgeries from January 12 to April 12 with IVF treatment restricted to cycles beginning prior to January 6
  • Furthermore, Queensland has suspended all non-urgent elective surgeries in public hospitals, with only its services undertaken in private day hospitals unaffected
  • Virtus Health is up 0.3 per cent on the market with shares trading at $6.68 each

Virtus Health (VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the State Governments cope with the current COVID-19 outbreak.

In NSW, the State Government has suspended all non-urgent elective surgeries from January 10, 2022.

This suspension does not apply to procedures where patients are admitted and discharged on the same day. Therefore, this does not restrict IVF or other services provided by Virtus.

The Victorian State Government has suspended all non-urgent elective surgeries from January 12 until April 12, with IVF treatments restricted to cycles beginning prior to January 6.

If the Victorian direction continues for those three months, Virtus’ Victorian clinics will reduce its activity during this period with steps being taken to ease the impact of the reduced activity.

Meanwhile, Queensland has suspended all non-urgent elective surgeries in public hospitals only, therefore Virtus’ IVF and other services undertaken in private day hospitals are not affected.

Additionally, this current COVID-19 wave is presenting staff shortages, increased testing requirements and the deferral of procedures.

As a result of all these challenges, Virtus cannot accurately provide any near-term financial impacts. A further update will be made on February 15.

Virtus Health was down 0.3 per cent on the market with shares trading at $6.68 at 12:22 pm AEDT.

VRT by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece